User: Guest

ENDOMETRIOSIS DRUGS

Global Market Trajectory & Analytics

MCP-6433

VALIDATED EXECUTIVE ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

4521

Interactions with Platform & by Email *

INTERACTIONS

814

Unique # Participated *

PARTICIPANTS

136

Responses Validated *

VALIDATIONS

61

* Login to view program details and full enterprise executive list.


  •  DATE

    JULY 2020

  •  TABLES

    54

  •  PAGES

    122

  •  EDITION

    18

  •  PRICE

    USD $5600


COVID-19 IMPACT SURVEY
Amid the COVID-19 crisis, the global market for Endometriosis Drugs estimated at US$1.8 Billion in the year 2020, is projected to reach a revised size of US$2.2 Billion by 2027, growing at aCAGR of 2.8% over the period 2020-2027. Hormone therapy, one of the segments analyzed in the report, is projected to record 3% CAGR and reach US$1.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Analgesics segment is readjusted to a revised 2.5% CAGR for the next 7-year period.
The Endometriosis Drugs market in the U.S. is estimated at US$524.5 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$387.4 Million by the year 2027 trailing a CAGR of 2.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.6% and 2.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.We bring years of research experience to this 18th edition of our report. The 122-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Competitors identified in this market include, among others, AbbVie Inc.; Astellas Pharma Inc.; AstraZeneca Plc; Bayer AG; Debiopharm Group; Evotec AG; Kissei Pharmaceutical Co. Ltd.; Neurocrine Biosciences Inc.; ObsEva SA; Pfizer Inc.; Repros Therapeutics Inc.; Takeda Pharmaceutical Company Limited; ValiRx plc
» Product Type (Hormone therapy, Analgesics)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

INSIDER ACCESS PRIVILEGES

Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.

  • A: 
    ACTIVE CLIENT
  • B: 
    INACTIVE CLIENT
  • C: 
    ACTIVE PANELIST
  • D: 
    INACTIVE PANELIST
  • E: 
    OPT-INS
  
REPORT INDEX PROJECT COMPENDIUM * EXPERT PANEL